NV CoV 2 R
Alternative Names: NV-CoV-2-RLatest Information Update: 23 Sep 2021
Price :
$50 *
At a glance
- Originator TheraCour Pharma
- Developer NanoViricides; TheraCour Pharma
- Class Adenine nucleotides; Amines; Antivirals; Esters; Furans; Nitriles; Phosphorus compounds; Polymers; Pyridazines; Pyrroles; Small molecules; Triazines
- Mechanism of Action RNA replicase inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 23 Sep 2021 Pharmacodynamics and pharmacokinetics data from a preclinical trial in COVID-2019 infections released by NanoViricides
- 08 Sep 2021 Antiviral SARS-CoV-2 drugs licensed to NanoViricides worldwide for the treatment/prevention of COVID-19 infections
- 25 Jun 2021 TheraCour Pharma files for patent protection for self-assembling amphiphilic polymers as anti-COVID-19 agents and compositions, formulations, processes, manufactured products, and methods of use in USA